Recent developments include BioVie's announcement of a $4.74 million registered direct offering, completion of enrollment in the Phase 2 ADDRESS-LC trial for Long COVID, and positive Phase 2 signals for bezisterim in Long COVID patients. The company also reported promising Phase 3 results for bezisterim in Alzheimer's disease despite trial challenges.

• BioVie announced a $4.74 million registered direct offering in November 2026, with shares falling 26% following the announcement [N1].
• Bezisterim showed positive signals in Long COVID patients with greater symptom burden in Phase 2 trials, indicating potential efficacy [N2].
• Phase 2 ADDRESS-LC topline data for bezisterim's potential in Long COVID was presented in September 2026 [N4].
• BioVie completed dosing the final patient in the Phase 2 trial for bezisterim in Long COVID in August 2026 [N5].
• The company reported promising Phase 3 study results for bezisterim in Alzheimer's disease at WCAG-2025 despite challenges with trial data integrity [N8].
• BioVie appointed Dr. Amy S. Chappell and Kameel D. Farag to its Board of Directors in July 2025 [N7].
• The company has been highlighted in weekly biotech news for driving deals and data releases related to its pipeline [N7].

BioVie's lead candidate bezisterim has demonstrated positive Phase 2b clinical signals in Parkinson's disease and is advancing clinical trials in Long COVID and Alzheimer's disease, indicating potential for novel treatments in large patient populations. The company's BIV201 program targets a significant unmet need in liver cirrhosis ascites with FDA designations supporting expedited development. Strong patent protection and ongoing clinical progress could support future regulatory approvals and commercial opportunities.

BioVie's clinical programs face risks including protocol deviations and regulatory challenges, as seen in the Alzheimer's Phase 3 trial with site exclusions leading to underpowered results. Reliance on third parties for clinical trials introduces operational risks. The company is in a net loss position with limited disclosed financial resources, and future equity offerings may dilute shareholders. Regulatory approvals remain uncertain, and clinical trial outcomes may not replicate early signals.

BioVie's moat is based on its proprietary drug candidates with novel mechanisms targeting neuroinflammation and insulin resistance, supported by patents on bezisterim and novel liquid formulations of terlipressin. The company has FDA Fast Track and Orphan Drug designations for BIV201, and its clinical-stage assets address significant unmet medical needs in neurodegenerative diseases and liver cirrhosis complications. The complexity of drug development, regulatory approvals, and intellectual property protection contribute to barriers for competitors.

• Clinical Trial Risks: BioVie depends on third parties to conduct clinical trials; failures or non-compliance with regulatory standards could delay approvals or require additional trials [S2].
• Regulatory and Data Integrity Risks: Significant protocol deviations and GCP violations in the Alzheimer's Phase 3 trial led to patient exclusions and underpowered endpoints, raising concerns about data robustness [S2].
• Financial Risks: The company reported a net loss of $5.6 million for the quarter ended September 30, 2026, with limited disclosed liquidity, and may need to raise capital through equity offerings, causing dilution [S2][N1].
• Market and Commercialization Risks: No drug candidate has yet received FDA approval; commercial success depends on regulatory approvals and market acceptance of novel therapies.

• BioVie Inc. is a clinical-stage company developing drug therapies for neurological/neurodegenerative disorders and advanced liver disease [S1].
• The company acquired NeurMedix's assets including bezisterim (NE3107), an investigational oral small molecule targeting inflammation-driven insulin resistance and neuroinflammation, with potential applications in Alzheimer's disease (AD), Parkinson's disease (PD), and Long COVID [S1].
• Bezisterim's mechanism involves inhibition of ERK and NFκB pathways, modulating inflammatory cascades without disrupting homeostatic functions [S1].
• Bezisterim has been tested in multiple clinical trials: Phase 2b SUNRISE-PD trial in early-stage PD showed statistically significant reduction in neuroinflammation biomarkers and improvements in motor/non-motor symptoms; well tolerated with safety comparable to placebo [S1].
• Phase 2 ADDRESS-LC trial for Long COVID completed enrollment in May 2026, evaluating bezisterim's efficacy on cognitive impairment and fatigue; topline results expected late summer 2026 [S1].
• Phase 3 trial in mild to moderate AD encountered significant protocol deviations and GCP violations at 15 sites, leading to exclusion of those patients and underpowered primary endpoints; preliminary signals of efficacy observed in compliant patient subset [S1].
• BIV201 (continuous infusion terlipressin) is under development for liver cirrhosis-related ascites; granted FDA Fast Track and Orphan Drug status; Phase 2 study showed reduction in ascites fluid volume; Phase 3 protocol design is being finalized following FDA guidance [S1].
• BioVie holds patents for bezisterim and novel liquid formulations of terlipressin with granted patents in multiple jurisdictions [S1].
• As of September 30, 2026, BioVie had $7.73 million in cash and equivalents, current assets of $10.45 million, current liabilities of $4.35 million, a current ratio of 2.4, and a cash ratio of 1.78 [S2].
• Net loss for the quarter ending September 30, 2026 was $5.6 million with basic and diluted EPS of -$0.68 [S2].
• The company relies on third parties such as CROs for clinical trials and retains ultimate regulatory responsibility; deviations or failures by third parties could delay approvals [S2].
• BioVie announced a $4.74 million registered direct offering in November 2026, which was associated with a 26% share price decline [N1].
• Recent news highlights positive Phase 2 signals for bezisterim in Long COVID patients with greater symptom burden and ongoing anticipation of topline data from ADDRESS-LC trial [N2][N3][N4][N5].
• The company has presented promising Phase 3 results for bezisterim in Alzheimer's disease at WCAG-2025, despite trial challenges [N8].
• BioVie has appointed new board members and continues to drive deals and data releases related to its pipeline [N7][N8].